New York State Common Retirement Fund
PRLD icon

New York State Common Retirement Fund’s Prelude Therapeutics PRLD Stock Holding History

New York State Common Retirement Fund’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,622
Closed -$2.78K – 3305
2025
Q1 		$2.78K Hold
3,622
– – ﹤0.01% 3146
2024
Q4 		$4.62K Hold
3,622
– – ﹤0.01% 3146
2024
Q3 		$7.5K Sell
3,622
-15,500
-81% -$71.8K ﹤0.01% 3125
2024
Q2 		$72.9K Sell
19,122
-1,000
-5% -$4.07K ﹤0.01% 2988
2024
Q1 		$95.4K Hold
20,122
– – ﹤0.01% 2760
2023
Q4 		$85.9K Sell
20,122
-27
-0.1% -$82 ﹤0.01% 2814
2023
Q3 		$62.3K Buy
20,149
+149
+0.7% +$559 ﹤0.01% 2938
2023
Q2 		$90K Buy
+20,000
New +$120K ﹤0.01% 2947
2022
Q3 		– Sell
-92
Closed – – 3411
2022
Q2 		$0 Sell
92
-4,900
-98% -$24.9K ﹤0.01% 3522
2022
Q1 		$34K Sell
4,992
-4,100
-45% -$37.5K ﹤0.01% 3237
2021
Q4 		$113K Sell
9,092
-17
-0.2% -$277 ﹤0.01% 3041
2021
Q3 		$285K Buy
9,109
+34
+0.4% +$1.1K ﹤0.01% 2747
2021
Q2 		$260K Buy
9,075
+75
+0.8% +$2.67K ﹤0.01% 2927
2021
Q1 		$390K Buy
9,000
+1,800
+25% +$119K ﹤0.01% 2555
2020
Q4 		$515K Buy
+7,200
New +$358K ﹤0.01% 2341

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

New York State Common Retirement Fund's PRLD Position: Q2 2025 in Review

New York State Common Retirement Fund sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 3,622 shares — an estimated $2.78K sold.

New York State Common Retirement Fund first reported a position in PRLD in Q4 2020 and held it in 15 quarters. The position peaked at $515K in Q4 2020. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • New York State Common Retirement Fund reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • New York State Common Retirement Fund sold 3,622 Prelude Therapeutics shares in Q2 2025, an estimated $2.78K.
  • New York State Common Retirement Fund first reported a position in Prelude Therapeutics in Q4 2020 and held it in 15 quarters.
  • New York State Common Retirement Fund's Prelude Therapeutics position peaked at $515K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on New York State Common Retirement Fund's 13F filing for Q2 2025, filed 13 Aug 2025.